相关临床试验
92
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
3.3%
已完成
40
43.5%
尚未招募
5
5.4%
招募中
14
15.2%
Temporarily Not Available
1
1.1%
终止
4
4.3%
Unknown
24
26.1%
撤回
1
1.1%
暂无批准数据
- A joint study from Korea University Guro Hospital and Seoul National University found sarcopenia predicts poorer immunotherapy outcomes in advanced non-small cell lung cancer patients. - Patients with sarcopenia experienced faster cancer progression and shorter duration of immune checkpoint inhibitor effectiveness compared to those without sarcopenia. - Sarcopenic patients showed more active inflammatory responses and higher expression of TIGIT, a protein linked to reduced immune cell function. - Researchers suggest evaluating sarcopenia alongside blood biomarkers could help establish personalized treatment strategies for NSCLC patients.
- Onconic Therapeutics has submitted an application to MFDS to expand Jaqbo's indication to include gastric ulcer treatment, following successful Phase 3 trial results showing 100% healing rate at 8 weeks. - The Phase 3 trial, involving 329 patients across 40 Korean medical institutions, demonstrated non-inferiority of Jaqbo compared to lansoprazole in treating gastric ulcers. - If approved in the first half of 2024, Jaqbo will become a dual-indication treatment for both erosive GERD and gastric ulcers, strengthening its potential as a global blockbuster drug.
